Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

4.5K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.5K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

7.1K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
7.1K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

6.8K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
6.8K
Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

5.8K
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
5.8K
Abnormal Proliferation02:23

Abnormal Proliferation

5.0K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.0K
Multipotency of Hematopoietic Stem Cells01:19

Multipotency of Hematopoietic Stem Cells

3.7K
The hematopoietic stem cells or HSCs are multipotent, meaning they can differentiate and give rise to all blood and immune cells. HSCs are maintained in the quiescent stage until an external stimulus initiates their differentiation. The multipotent HSCs exist as two heterogeneous populations, long-term repopulating cells (LTRC) and short-term repopulating cells (STRC). The two HSC populations have different surface markers or receptors and are classified based on quiescence and long-term...
3.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

HLA-E-Directed Accumulation of KIR<sup>+</sup>NKG2C<sup>+</sup> NK Cells upon HCMV Peptide Presentation In Vitro: Association with the Ex Vivo Phenotype.

International journal of molecular sciences·2026
Same author

Interplay of telomerase non-canonical functions in NK cell resistance to iCasp9-mediated apoptosis.

Cell death discovery·2026
Same author

In Search of Adaptive-Like Features of NK Cells Co-Expressing NKG2C and NKG2A.

Immune network·2026
Same author

(Re)defining the human chromatome: an integrated meta-analysis of localization, function, abundance, physical properties, and domain composition of chromatin proteins.

Nucleic acids research·2026
Same author

H2A.Z and H3:K56Q Affect Transcription Through Chromatin and Yeast FACT-Dependent Nucleosome Unfolding.

International journal of molecular sciences·2025
Same author

Histone tetrasome dynamics affects chromatin transcription.

Nucleic acids research·2025

Related Experiment Video

Updated: Dec 27, 2025

Intracellular Refolding Assay
07:18

Intracellular Refolding Assay

Published on: January 24, 2012

14.6K

HSP70 Multi-Functionality in Cancer.

Zarema Albakova1,2, Grigoriy A Armeev1, Leonid M Kanevskiy2

  • 1Department of Biology, Lomonosov Moscow State University, 119192 Moscow, Russia.

Cells
|March 4, 2020
PubMed
Summary

Heat shock proteins (HSP70s) are crucial for cancer survival, promoting tumor growth and metastasis. Targeting HSP70 offers a promising strategy for developing novel anti-cancer therapies.

Keywords:
HSP70apoptosisauthophagycancerexosomesimmunotherapymetastasissenescence

More Related Videos

Ex Vivo Treatment Response of Primary Tumors and/or Associated Metastases for Preclinical and Clinical Development of Therapeutics
08:29

Ex Vivo Treatment Response of Primary Tumors and/or Associated Metastases for Preclinical and Clinical Development of Therapeutics

Published on: October 2, 2014

15.1K
From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia
10:18

From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia

Published on: October 19, 2014

14.1K

Related Experiment Videos

Last Updated: Dec 27, 2025

Intracellular Refolding Assay
07:18

Intracellular Refolding Assay

Published on: January 24, 2012

14.6K
Ex Vivo Treatment Response of Primary Tumors and/or Associated Metastases for Preclinical and Clinical Development of Therapeutics
08:29

Ex Vivo Treatment Response of Primary Tumors and/or Associated Metastases for Preclinical and Clinical Development of Therapeutics

Published on: October 2, 2014

15.1K
From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia
10:18

From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia

Published on: October 19, 2014

14.1K

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • 70-kDa heat shock proteins (HSP70s) are overexpressed in various cancers.
  • HSP70s confer a survival advantage to malignant cells by inhibiting apoptosis and promoting other cancer hallmarks.

Purpose of the Study:

  • To review the multifaceted roles of HSP70 in cancer progression.
  • To highlight the therapeutic potential of targeting HSP70.

Main Methods:

  • Literature review of HSP70 functions in cancer.
  • Analysis of HSP70's involvement in cancer hallmarks.
  • Overview of current and emerging HSP70-targeted therapies.

Main Results:

  • HSP70 suppresses apoptosis, regulates necrosis, bypasses senescence, impacts tumor immunity, and promotes angiogenesis and metastasis.
  • Cancer cells exhibit a strong dependence on HSP70 for survival and growth.
  • Extracellular HSP70 release influences patient survival outcomes.

Conclusions:

  • HSP70 is a critical regulator of multiple cancer hallmarks, explaining cancer's "addiction" to this protein.
  • Understanding HSP70's dynamic nature is key for developing effective anti-cancer strategies.
  • Targeting HSP70 through small molecule inhibitors and immunotherapy shows therapeutic promise.